Researcher profile

Muhammad Ismail

Muhammad Ismail contributes to research discovery and scholarly infrastructure.

ResearcherAffiliation not importedOpen to collaborate

Trust snapshot

Quick read

Trust 17 - UnverifiedVerification L1Unclaimed author
4works
0followers
4topics
4close collaborators

Actions

Decide how to stay connected

Follow researcher0

Identity and collaboration

How to connect with this researcher

Claiming links this public author record to a researcher profile and unlocks direct collaboration workflows.

Log in to claim

Direct collaboration

Open a focused conversation when the fit is right

Claim this author entity first to unlock direct invitations.

Research graph

See the researcher in context

Open full explorer

Inspect adjacent work, topics, institutions and collaborators without jumping out to a separate graph page.

Building this graph slice

BZPEER is loading the nearby papers, people, topics and institutions for this page.

Published work

4 published item(s)

preprint2022arXiv

Clustered Scheduling and Communication Pipelining For Efficient Resource Management Of Wireless Federated Learning

This paper proposes using communication pipelining to enhance the wireless spectrum utilization efficiency and convergence speed of federated learning in mobile edge computing applications. Due to limited wireless sub-channels, a subset of the total clients is scheduled in each iteration of federated learning algorithms. On the other hand, the scheduled clients wait for the slowest client to finish its computation. We propose to first cluster the clients based on the time they need per iteration to compute the local gradients of the federated learning model. Then, we schedule a mixture of clients from all clusters to send their local updates in a pipelined manner. In this way, instead of just waiting for the slower clients to finish their computation, more clients can participate in each iteration. While the time duration of a single iteration does not change, the proposed method can significantly reduce the number of required iterations to achieve a target accuracy. We provide a generic formulation for optimal client clustering under different settings, and we analytically derive an efficient algorithm for obtaining the optimal solution. We also provide numerical results to demonstrate the gains of the proposed method for different datasets and deep learning architectures.

preprint2022arXiv

Drug Repurposing For SARS-COV-2 Using Molecular Docking

Drug repurposing is an unconventional approach that is used to investigate new therapeutic aids of existing and shelved drugs. Recent advancement in technologies and the availability of the data of genomics, proteomics, transcriptomics, etc., and with the accessibility of large and reliable database resources, there are abundantly of opportunities to discover drugs by drug repurposing in an efficient manner. The recent pandemic of SARS-COV-2, that caused the death of 6,245,750 human beings to date, has tremendously increase the exceptional usage of bioinformatics tools in interpreting the molecular characterizations of viral infections. In this paper, we have employed various bioinformatics tools such as AutoDock-Vina, PyMol etc. We have found a leading drug candidate Cepharanthine that has shown better results and effectiveness than recently used antiviral drug candidates such as Favipiravir, IDX184, Remedesivir, Ribavirin and etc. This paper has analyzed Cepharanthine potential therapeutic importance as a drug of choice in managing COVID-19 cases. It is anticipated that proposed study would be beneficial for researchers and medical practitioners in handling SARS-CoV-2 and its variant related diseases.

preprint2022arXiv

Vehicle-to-Vehicle Charging Coordination over Information Centric Networking

Cities around the world are increasingly promoting electric vehicles (EV) to reduce and ultimately eliminate greenhouse gas emissions. For example, the city of San Francisco aims to increase the number of EVs from tens of thousands to over quarter of a million by 2025. This huge number of EVs will put unprecedented stress on the power grid. To efficiently serve the increased charging load, these EVs need to be charged in a coordinated fashion. One promising coordination strategy is vehicle-to-vehicle (V2V) charging coordination, enabling EVs to sell their surplus energy in an ad-hoc, peer to peer manner. Enabling V2V charging coordination requires new communication network protocols that can facilitate such charging coordination in a peer-to-peer fashion. This paper introduces an Information Centric Networking (ICN)-based protocol to support ad-hoc V2V charging coordination (V2V-CC). Our evaluations demonstrate that V2V-CC can provide added flexibility, fault tolerance, and reduced communication latency than a conventional centralized cloud based approach. We show that V2V-CC can achieve a 93\% reduction in protocol completion time compared to a conventional approach. We also show that V2V-CC also works well under extreme packet loss, making it ideal for V2V charging coordination.

preprint2020arXiv

Metastatic melanoma-A review of current and future perspective

Metastatic Melanoma, the fifth most common cancer in the western countries and the most common malignancy diagnosed in United States present itself as the most lethal treatment resistant cancer worldwide. In addition to the reactive oxygen species(ROS), mutations in the genes encoding receptors and non-receptor tyrosine/serene/threonine protein kinases are known to be involved in its etiology. Kinases are molecular players of cell survival, growth, and proliferation and migration that mediate their effects via various signal transduction pathways. A number of such molecular players have been previously found to be mutated and hyper phosphorylated in melanoma. Although, several systemic therapies including cytotoxic chemotherapy, targeted drugs, hormonal therapy, radiation therapy, bio-chemotherapy, and therapies that inhibit negative regulation of immune system have been approved from U. S. Food and Drug Administration (FDA) for metastatic melanoma treatment. However, no systemic therapy has meaningfully changed its survival end points so far and surgery still presents primary treatment option for advanced and metastatic melanomaa due to its highly resistant nature towards systemic drugs, high rate of severe, life-threatening, or fatal side effects, and un satisfactory overall response rate. Therefore, there is still a need to develop therapies that target the unique molecular profile of melanoma tumors.